Previous Close | 4.4300 |
Open | 4.4800 |
Bid | 4.8400 x 1800 |
Ask | 4.8500 x 3000 |
Day's Range | 4.4300 - 4.8950 |
52 Week Range | 1.4300 - 5.7600 |
Volume | |
Avg. Volume | 6,381,586 |
Market Cap | 470.892M |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9020 |
Earnings Date | Mar 15, 2022 - Mar 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.53 |
Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET. On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2022.